DTC Restrictions Ahead: Risk Management Plans, “Drug Watch” Are Vehicles
Executive Summary
FDA will manifest its tougher stance on DTC advertising in requirements for more extensive risk management plans, Hogan & Hartson Partner Robert Brady predicted at a Regulatory Affairs Professionals Society conference in Chicago
You may also be interested in...
Industry-Sponsored CME Still On FDA Radar, McNeil Exec Says
Industry-sponsored continuing medical education remains on the radar at FDA, McNeil Consumer & Specialty Pharmaceuticals VP-Medical Regulatory Affairs Minnie Baylor-Henry said
Industry-Sponsored CME Still On FDA Radar, McNeil Exec Says
Industry-sponsored continuing medical education remains on the radar at FDA, McNeil Consumer & Specialty Pharmaceuticals VP-Medical Regulatory Affairs Minnie Baylor-Henry said
FDA Urges Greater Compliance With Ad Submission Regulations
Industry needs to improve compliance with regulations requiring the submission of promotional materials to the agency, CDER Division of Drug Marketing, Advertising & Communications Regulatory Counsel Kristin Davis said